Loading...
XSHE
002275
Market cap1.14bUSD
Jul 10, Last price  
13.12CNY
1D
-0.38%
1Q
-7.87%
Jan 2017
-28.58%
IPO
-48.42%
Name

Guilin Sanjin Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHE:002275 chart
P/E
17.80
P/S
3.77
EPS
0.74
Div Yield, %
4.18%
Shrs. gr., 5y
0.35%
Rev. gr., 5y
5.48%
Revenues
2.05b
-6.76%
797,851,762893,048,449986,157,9501,110,828,532983,460,3951,161,780,7611,311,546,6401,469,329,7431,466,351,7721,390,929,2551,525,223,9961,616,016,1871,584,673,4311,640,423,7301,566,484,6731,741,224,5511,959,732,8452,171,603,3632,193,992,0292,045,730,836
Net income
433m
-16.95%
194,803,906249,177,709273,726,598302,534,129258,757,964291,953,755331,151,951421,988,235444,866,407376,532,794393,660,041464,402,337413,346,109392,142,685277,020,907343,718,944329,526,523421,298,790521,533,564433,134,151
CFO
708m
+20.36%
217,665,767164,390,698190,965,906363,289,565285,487,714341,049,794302,589,346314,159,410396,529,896398,495,405536,851,083387,823,159551,726,197468,285,131597,991,408410,241,541528,666,938549,245,571588,331,526708,121,274
Dividend
Nov 19, 20250.2 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guilin Sanjin Pharmaceutical Co., Ltd. is a Chinese pharmaceutical firm dedicated to the research, production, and distribution of traditional Chinese and natural medicines across China. Established in 1967 and headquartered in Guilin, the company's product portfolio prominently features well-known traditional Chinese medicine (TCM) brands such as Guilin watermelon frost and lozenge, Sanjin tablets, and Naomaitai capsules. Beyond these core offerings, it also manufactures a range of other TCM preparations. The company operates as a subsidiary of the broader Guilin SanJin Group Co.,Ltd.
IPO date
Jul 10, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT